Save up to 90% on Talquetamab-TGVS with Coupons, Discount Cards & Patient Assistance Programs

Talquetamab-TGVS is available as a subcutaneous injection that contains 3 mg/1.5 mL (2 mg/mL) or 40 mg/mL.

• Talquetamab-TGVS is a bispecific GPRC5D-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody

Talquetamab-TGVS works by helping your immune system slow or stop the spread of cancer cells.

• Talquetamab-TGVS is given as a subcutaneous injection on a weekly or biweekly schedule. Your dose is based on your weight and will start low and gradually increase

Talquetamab-TGVS is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Talquetamab-TGVS:

• Fever
• Foul or metallic taste in your mouth
• Nail disorder
• Musculoskeletal pain
• Skin disorder
• Rash
• Fatigue
• Weight decreased
• Dry mouth
• Dry skin
• Difficulty swallowinig
• Upper respiratory tract infection
• Diarrhea
• Hypotension
• Headache

Serious side effects are rare with Talquetamab-TGVS. Call your healthcare provider or get medical help right away if you develop any of the following:

• Cytokine Release Syndrome (CRS)
• Neurological problems

The following medications may interact with Talquetamab-TGVS:

• For certain cytochrome P450 (CYP) substrates, minimal changes in the substrate concentration may lead to serious adverse reactions. Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with Talquetamab-TGVS

Various FDA-approved generic manufacturers

Based on its mechanism of action, Talquetamab-TGVS may cause fetal harm when administered to a pregnant woman. If you can become pregnant, you should use effective contraception during treatment with Talquetamab-TGVS and for 3 months after the last dose.

• Talvey